Indo Us Bio-Tech appoints Hemanshi Darsh Soni as Independent Director after Patel's resignation

What Indo Us Bio‑Tech announced

Indo Us Bio‑Tech Ltd filed a corporate action notice with the Bombay Stock Exchange on 10 July 2026. The filing disclosed two related governance updates: the resignation of an existing non‑executive independent director and the appointment of a new independent director, followed by the reconstitution of the board’s committees. Both actions are aimed at maintaining compliance with the Securities and Exchange Board of India (SEBI) Listing Obligations and Disclosure Requirements (LODR) and the Companies Act, 2013.

Resignation of Mrs. Nehaben Patel

On 21 April 2026, Mrs. Nehaben Patel (DIN: 09263180) tendered her resignation from the office of Non‑Executive Independent Director of Indo Us Bio‑Tech Ltd. The resignation was accepted by the board in a meeting held on the same day. The filing does not provide a reason for the resignation, nor does it indicate any impact on the company’s operations or shareholding structure. As an independent director, Mrs. Patel’s role would have been to provide unbiased oversight and to safeguard minority shareholder interests, a function that the board now seeks to continue through a new appointment.

Appointment of Mrs. Hemanshi Darsh Soni

Following the vacancy created by Mrs. Patel’s departure, the board appointed Mrs. Hemanshi Darsh Soni (DIN: 11659183) as an Additional Director (Non‑Executive, Independent) on 21 April 2026. The appointment is subject to approval by the shareholders at the forthcoming annual general meeting, as required under Section 149 of the Companies Act, 2013. Mrs. Soni will join the board as an independent director, bringing her own professional experience to the oversight function. The filing does not disclose any remuneration, shareholding, or other contractual terms associated with her appointment.

Reconstitution of Board Committees

A subsequent board meeting was held on Friday, 10 July 2026, from 15:00 to 15:30, during which the directors approved the reconstitution of the composition of the board’s committees. The reconstitution takes effect on the same day, 10 July 2026. While the notice does not list the specific committees affected (such as Audit, Nomination & Remuneration, or Stakeholder Relationship committees), it states that the changes are intended to ensure compliance with SEBI (LODR) Regulations, 2015 and the Companies Act, 2013. Reconstitution typically involves adjusting the membership to meet the statutory requirement for a minimum number of independent directors on key committees, thereby strengthening governance standards.

Key facts at a glance

Why this matters for investors

The changes are purely governance‑related and do not involve any alteration to the company’s capital structure, debt profile, or commercial contracts. However, maintaining the required number of independent directors and properly constituted committees is a statutory obligation. Non‑compliance can attract regulatory penalties or affect the company’s eligibility to list on the exchange. By promptly filling the independent director vacancy and reconstituting its committees, Indo Us Bio‑Tech demonstrates adherence to best‑practice corporate governance, which can be viewed positively by institutional investors who monitor board independence as a risk metric. The appointment remains contingent on shareholder approval, a standard procedural step that does not, in itself, imply any material risk.

Conclusion

Indo Us Bio‑Tech Ltd has addressed the resignation of Mrs. Nehaben Patel by appointing Mrs. Hemanshi Darsh Soni as an additional independent director, pending shareholder endorsement. Simultaneously, the board restructured its committees to align with SEBI and Companies Act requirements, effective 10 July 2026. No financial or operational implications were disclosed, and the filing indicates that the company is focused on maintaining regulatory compliance and robust board oversight.